AlibabaSettles $600M Fine Amid U.S. Pharma Import Allegations

The Chinese tech giant Alibaba will pay $600 million to resolve a dispute with U.S. authorities over claims that its platforms facilitated the sale and import of illegal pharmaceuticals, controlled substances, regulated chemicals, and pill-manufacturing equipment into the United States.

Alibaba manages some of the world’s leading e-commerce platforms, such as Alibaba.com and AliExpress.com, which were central to the allegations.

The U.S. government asserts that Alibaba’s U.S. payment processor, AUS Merchant Services, knowingly allowed merchants to sell and import prohibited items, violating federal regulations governing pharmaceuticals and controlled substances.

Under the settlement, Alibaba admits that from 2016 to 2024, its compliance measures failed to prevent approximately 80,000 transactions involving unlawful imports, which breached the Federal Food, Drug, and Cosmetic Act and other U.S. laws.

Alibaba acknowledges that employees raised concerns about inadequate compliance controls, and in some cases, merchants used the platform’s messaging system to redirect buyers to external communication channels for illicit sales.

The company stated in a statement that the resolution reflects a collaborative effort with U.S. regulators to strengthen oversight of third-party merchant activity on its platforms.

Agencies including the FDA, FDIC, IRS-Criminal Investigation, and others conducted over 40 undercover operations to purchase illegal pharmaceuticals and equipment, as reported in the settlement documentation. A non-prosecution agreement was finalized between Alibaba and the Justice Department.

IRS Criminal Investigations’ Chief Jarod Koopman emphasized the case’s significance, stating, “This resolution highlights IRS Criminal Investigation’s commitment to holding companies accountable and ensuring strict adherence to federal laws in the U.S.”

Source link